Company intelligence / Profile preview

BGI Group

Shenzhen, Guangdong, Chinaen.genomics.cn ↗

Ownership: Private
Employees: ~7000
Development stage: Commercial

Overview

BGI Group has established itself as a global leader in genomics research and clinical diagnostics. Its COVID‑19 RT-PCR test kits were among the first to receive WHO Emergency Use Listing. The company’s non-invasive prenatal testing solutions are widely used globally. It operates large-scale genome projects for humans and other species. No direct clinical trial results as it does not develop drugs.

Therapeutic areas: Infectious DiseasesRare DiseasesWomen's Health
Modalities: Sequencing platformDiagnostic products
Industry: Molecular Diagnostics

Partnerships

Technopark Biogen in Kazakhstan for Astana Genetic CenterMinistry of Health of Brunei for national cervical cancer screening program

Beyond the preview

Go deeper on BGI Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGI Group.

Explore the full profile